JP6374959B2 - Ｄｎａ−ｐｋ阻害剤 - Google Patents
Ｄｎａ−ｐｋ阻害剤 Download PDFInfo
- Publication number
- JP6374959B2 JP6374959B2 JP2016523925A JP2016523925A JP6374959B2 JP 6374959 B2 JP6374959 B2 JP 6374959B2 JP 2016523925 A JP2016523925 A JP 2016523925A JP 2016523925 A JP2016523925 A JP 2016523925A JP 6374959 B2 JP6374959 B2 JP 6374959B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- mmol
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1cnc(*)cc1 Chemical compound Cc1cnc(*)cc1 0.000 description 20
- AKPUZJOEQGBKPY-HSHIGALWSA-N C/C=N\C=C(\C)/C=C Chemical compound C/C=N\C=C(\C)/C=C AKPUZJOEQGBKPY-HSHIGALWSA-N 0.000 description 1
- HPZXEWQLFFUHHD-UHFFFAOYSA-N CC(COc1ccccc1Br)=C Chemical compound CC(COc1ccccc1Br)=C HPZXEWQLFFUHHD-UHFFFAOYSA-N 0.000 description 1
- SGYAHQJEQHTWHR-VOTSOKGWSA-N CC1(C)c2cccc(/C=C/[N+]([O-])=O)c2OC1 Chemical compound CC1(C)c2cccc(/C=C/[N+]([O-])=O)c2OC1 SGYAHQJEQHTWHR-VOTSOKGWSA-N 0.000 description 1
- HNCLOAJZDAMBQR-UHFFFAOYSA-N CC1(C)c2cccc(C=O)c2OC1 Chemical compound CC1(C)c2cccc(C=O)c2OC1 HNCLOAJZDAMBQR-UHFFFAOYSA-N 0.000 description 1
- FHRIFPIEZKZPBE-UHFFFAOYSA-N CC1(C)c2cccc(CCN)c2OC1 Chemical compound CC1(C)c2cccc(CCN)c2OC1 FHRIFPIEZKZPBE-UHFFFAOYSA-N 0.000 description 1
- SNOPQSLWDMEXLN-UHFFFAOYSA-N CC1(C)c2cccc(CCNc3cc(-c4ccc(N5CCN(C)CC5)nc4)ncn3)c2OC1 Chemical compound CC1(C)c2cccc(CCNc3cc(-c4ccc(N5CCN(C)CC5)nc4)ncn3)c2OC1 SNOPQSLWDMEXLN-UHFFFAOYSA-N 0.000 description 1
- MNUVJIPQYZJXAV-UHFFFAOYSA-N CC1(C)c2cccc(CCNc3cc(Cl)ncn3)c2OC1 Chemical compound CC1(C)c2cccc(CCNc3cc(Cl)ncn3)c2OC1 MNUVJIPQYZJXAV-UHFFFAOYSA-N 0.000 description 1
- BEIGEFOVGRASOO-UHFFFAOYSA-N CC1(C)c2ccccc2OC1 Chemical compound CC1(C)c2ccccc2OC1 BEIGEFOVGRASOO-UHFFFAOYSA-N 0.000 description 1
- XOGDXTACOCVNOT-UHFFFAOYSA-N CC1(C23C)C=NC2=CC(C)=CC=C3N=C1 Chemical compound CC1(C23C)C=NC2=CC(C)=CC=C3N=C1 XOGDXTACOCVNOT-UHFFFAOYSA-N 0.000 description 1
- MVTHDBVIVSNEHZ-UHFFFAOYSA-N Cc(cc1N=C)ccc1SC Chemical compound Cc(cc1N=C)ccc1SC MVTHDBVIVSNEHZ-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N Clc1cc(Cl)ncn1 Chemical compound Clc1cc(Cl)ncn1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N Oc1ccccc1Br Chemical compound Oc1ccccc1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 | 2013-10-17 | ||
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
| PCT/US2014/061033 WO2015058031A1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533366A JP2016533366A (ja) | 2016-10-27 |
| JP2016533366A5 JP2016533366A5 (enExample) | 2017-11-24 |
| JP6374959B2 true JP6374959B2 (ja) | 2018-08-15 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523925A Active JP6374959B2 (ja) | 2013-10-17 | 2014-10-17 | Ｄｎａ−ｐｋ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (enExample) |
| JP (1) | JP6374959B2 (enExample) |
| CN (1) | CN105636958B (enExample) |
| AU (1) | AU2014337208B2 (enExample) |
| BR (1) | BR112016008423B1 (enExample) |
| CA (1) | CA2927392C (enExample) |
| DK (1) | DK3057959T3 (enExample) |
| ES (1) | ES2671354T3 (enExample) |
| HR (1) | HRP20180804T1 (enExample) |
| HU (1) | HUE037516T2 (enExample) |
| LT (1) | LT3057959T (enExample) |
| PL (1) | PL3057959T3 (enExample) |
| PT (1) | PT3057959T (enExample) |
| RS (1) | RS57306B1 (enExample) |
| SI (1) | SI3057959T1 (enExample) |
| TR (1) | TR201807411T4 (enExample) |
| WO (1) | WO2015058031A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| EA201992676A1 (ru) * | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| US12269804B2 (en) | 2018-01-17 | 2025-04-08 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| BR112020014140A2 (pt) | 2018-01-17 | 2020-12-01 | Vertex Pharmaceuticals Incorporated | inibidores de dna-pk |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| CA3124353A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| KR102786205B1 (ko) * | 2019-12-31 | 2025-03-31 | 청두 바이위 파머수티컬 씨오., 엘티디 | 퓨린 유도체 및 의학에서의 그의 용도 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202604507A (zh) | 2024-05-02 | 2026-02-01 | 瑞士商愛杜西亞製藥有限公司 | 經n-取代之吲哚衍生物的結晶形式 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| US8084457B2 (en) * | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| EP1901747A2 (en) * | 2005-05-25 | 2008-03-26 | Ingenium Pharmaceuticals AG | Pyrimidine-based cdk inhibitors for treating pain |
| AU2007305016B2 (en) * | 2006-10-02 | 2011-11-03 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| EA201201274A1 (ru) * | 2010-03-10 | 2013-04-30 | Инджениум Фармасьютиклз Гмбх | Ингибиторы протеинкиназ |
| SG11201406584TA (en) * | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
-
2014
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en not_active Ceased
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 HR HRP20180804TT patent/HRP20180804T1/hr unknown
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105636958A (zh) | 2016-06-01 |
| RS57306B1 (sr) | 2018-08-31 |
| PL3057959T3 (pl) | 2018-08-31 |
| EP3057959A1 (en) | 2016-08-24 |
| ES2671354T3 (es) | 2018-06-06 |
| PT3057959T (pt) | 2018-06-04 |
| HRP20180804T1 (hr) | 2018-08-10 |
| BR112016008423B1 (pt) | 2022-02-22 |
| AU2014337208B2 (en) | 2018-05-24 |
| HUE037516T2 (hu) | 2018-09-28 |
| DK3057959T3 (en) | 2018-06-06 |
| LT3057959T (lt) | 2018-06-11 |
| CA2927392A1 (en) | 2015-04-23 |
| CA2927392C (en) | 2021-11-09 |
| SI3057959T1 (en) | 2018-07-31 |
| WO2015058031A1 (en) | 2015-04-23 |
| EP3057959B1 (en) | 2018-02-28 |
| JP2016533366A (ja) | 2016-10-27 |
| BR112016008423A2 (enExample) | 2017-08-01 |
| CN105636958B (zh) | 2018-01-05 |
| TR201807411T4 (tr) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6741825B2 (ja) | Ｄｎａ−ｐｋ阻害剤 | |
| JP2016533366A (ja) | Ｄｎａ−ｐｋ阻害剤 | |
| AU2014337208A1 (en) | DNA-PK inhibitors | |
| HK40003569B (en) | Dna-pk inhibitors | |
| HK40003569A (en) | Dna-pk inhibitors | |
| HK1207859B (en) | Dna-pk inhibitors | |
| HK1208022B (en) | Dna-pk inhibitors | |
| HK1228386A1 (en) | Dna-pk inhibitors | |
| HK1228386B (en) | Dna-pk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180622 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180720 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6374959 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |